Zydus Lifesciences rises on getting USFDA`s final nod for Oxcarbazepine Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences rises on getting USFDA’s final nod for Oxcarbazepine Tablets
Jul-05-2023 14:06 Hrs IST
Zydus Lifesciences is currently trading at Rs. 582.10, up by 7.80 points or 1.36% from its previous closing of Rs. 574.30 on the BSE.
The scrip opened at Rs. 574.85 and has touched a high and low of Rs. 583.25 and Rs. 573.90 respectively. So far 23649 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 594.60 on 03-Jul-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022.
Last one week high and low of the scrip stood at Rs. 594.60 and Rs. 570.80 respectively. The current market cap of the company is Rs. 58920.40 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg (USRLD: Trileptal Tablets, 150 mg, 300 mg, and 600 mg).
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India). Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of $105 million in the United States (IQVIA MAT May 2023).
The group now has 374 approvals and has so far filed over 442 ANDAs as of March 31, 2023 since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
